Clinical trials: Inflammatory
Pain, Inflammatory
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
This study is the first administration of GSK3858279 in humans and will be conducted in two parts: Part A will consist of a single ascending dose escalation design to evaluate safety, tolerability, PK, TE and immunogenicity of…
- Trial name
- NCT03485365
- Testing
- GSK3858279 IV, GSK3858279 SC
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01576367
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)
The objective of this observational study was to assess changes in fecal calprotectin levels and its suitability as a monitoring tool in participants with moderate-to-severe Crohn's Disease who were treated with adalimumab.
- Trial name
- FAIR (NCT01759264)
- Volunteers
- 101 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.
- Trial name
- NCT03269695
- Testing
- PF-06687234
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
Innate Inflammatory Response, Vaccination
PFAS Exposure and Immune Response to Vaccination in Adults
This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine.
- Conditions
- Innate Inflammatory Response, Vaccination, Diphtheria, Tetanus
- Trial name
- NCT06588530
- Testing
- TENIVAC
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Rheumatoid Arthritis, Psoriatic Arthritis
Surveillance of Humira Injection in Korean Patients
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- NCT01083121
- Where
- 77 sites in South Korea
- Volunteers
- 1,779 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Sepsis, Septic Shock
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving…
- Trial name
- NCT00279214
- Testing
- drotrecogin alfa (activated)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Rheumatologic Disorder, Inflammatory Bowel Diseases
Flu Vaccine Response in Patients on Biologic Therapies
This proposed study will assess the immunogenicity, safety, and clinical efficacy of an influenza vaccine booster dose strategy in patients with autoimmune diseases who are receiving immunosuppressive therapies.
- Conditions
- Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
- Trial name
- NCT03277703
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stony Brook University
Colitis, Ulcerative, Inflammatory Bowel Disease
Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis
To assess if infliximab drug levels in subjects with Ulcerative Colitis predict risk of colectomy rate. Additionally, the investigators will estimate an optimal day 4 infliximab level based on the study results.
- Conditions
- Colitis, Ulcerative, Inflammatory Bowel Disease, IBD
- Trial name
- NCT02438410
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma
Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
This phase II trial studies how well giving accelerated radiation therapy (RT) after surgery works in treating patients with breast cancer. RT uses high energy x rays to kill tumor cells.
- Conditions
- Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Mucinous Ductal Breast Carcinoma
- Trial name
- NCT01417286
- Testing
- External beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Rutgers, The State University of New Jersey
Alcoholic Hepatitis
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe…
- Trial name
- AH (NCT03432260)
- Testing
- DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Durect
Crohn Disease
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
The primary objective of the study was to investigate long-term safety of risankizumab (BI 655066/ABBV-066) in participants with moderately to severely active Crohn's disease who showed a clinical response or remission on…
- Trial name
- NCT02513459
- Testing
- Risankizumab 600 mg IV, Risankizumab 180 mg SC
- Where
- 28 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- AbbVie
Sepsis, Disease Progression
Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
To investigate the role of initial venous lactate in predicting the severity progression to overt septic shock and 30-day mortality in non-elderly patients without hemodynamic shock who suspected to have acute infections.
- Conditions
- Sepsis, Disease Progression, Septic Shock, Fatal Outcome
- Trial name
- NCT01947127
- Where
- Thailand
- Volunteers
- 458 people
- Sponsor
- Chulalongkorn University
Sepsis
A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)
Sepsis is a common inflammatory response to infection characterized by hypovolemia and vasodilation for which early administration of intravenous fluids has been suggested to improve outcomes.
- Trial name
- BALANCE (NCT02159079)
- Testing
- Conservative Fluid Management Strategy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University
Crohn's Disease, Spondyloarthritis
Imaging Biomarkers in Crohn's Associated Spondyloarthritis
In patients with Crohn's Disease, symptoms of inflammatory back pain (IBP) precede changes on plain X-rays by years, and MRI changes of axial inflammation precede development of X-ray changes.
- Trial name
- MaRCH-on (NCT02709694)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Hospital for Special Surgery, New York
Crohn's Disease
Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
The purpose of this study is to evaluate the long-term safety and tolerability of certolizumab pegol (CZP) treatment in children and adolescents with moderately to severely active Crohn's disease.
- Trial name
- NCT01190410
- Testing
- certolizumab pegol
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 16 people
- Sponsor
- UCB Pharma
Ulcerative Colitis
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.
- Trial name
- SEA TURTLE (NCT04577794)
- Testing
- GLPG3970
- Where
- 15 sites in Georgia, Moldova and 2 more
- Volunteers
- 31 people
- Sponsor
- Lakefront Biotherapeutics NV
Inflammatory Bowel Disease
Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants
This is a Phase 1, single-center, randomized, double-blind, third-party open (ie, participant blind, investigator blind and sponsor open), placebo controlled study to investigate PK, safety, tolerability, immunogenicity, and PD…
- Trial name
- NCT05107492
- Testing
- 450mg, 150mg
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Crohn Disease
A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease. The purpose of this study is to find out whether BI 706321 combined with ustekinumab helps people with Crohn's disease.
- Trial name
- NCT04978493
- Testing
- BI 706321, Ustekinumab
- Where
- 49 sites in United States, Belgium and 9 more
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Ulcerative Colitis, Inflammatory Bowel Disease
A Trial of Rosiglitazone for Ulcerative Colitis
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating rosiglitazone: 4 mg tablets or placebo tablets administered orally twice daily for 12 weeks.
- Trial name
- NCT00065065
- Testing
- Rosiglitazone
- Where
- 13 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- James Lewis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.